| Literature DB >> 34854455 |
Robert Mills-Goodlet1, Litty Johnson1, Isabel J Hoppe1,2, Christof Regl1, Mark Geppert1, Milena Schenck3, Sara Huber1, Michael Hauser1, Fátima Ferreira1, Nicola Hüsing3, Christian G Huber1,2, Hans Brandstetter1,2, Albert Duschl1, Martin Himly1.
Abstract
A detailed description of the changes that occur during the formation of protein corona represents a fundamental question in nanoscience, given that it not only impacts the behaviour of nanoparticles but also affects the bound proteins. Relevant questions include whether proteins selectively bind particles, whether a specific orientation is preferred for binding, and whether particle binding leads to a modulation of their 3D fold. For allergens, it is important to answer these questions given that all these effects can modify the allergenic response of atopic individuals. These potential impacts on the bound allergen are closely related to the specific properties of the involved nanoparticles. One important property influencing the formation of protein corona is the nanotopography of the particles. Herein, we studied the effect of nanoparticle porosity on allergen binding using mesoporous and non-porous SiO2 NPs. We investigated (i) the selectivity of allergen binding from a mixture such as crude pollen extract, (ii) whether allergen binding results in a preferred orientation, (iii) the influence of binding on the conformation of the allergen, and (iv) how the binding affects the allergenic response. Nanotopography was found to play a major role in the formation of protein corona, impacting the physicochemical and biological properties of the NP-bound allergen. The porosity of the surface of the SiO2 nanoparticles resulted in a higher binding capacity with pronounced selectivity for (preferentially) binding the major birch pollen allergen Bet v 1. Furthermore, the binding of Bet v 1 to the mesoporous rather than the non-porous SiO2 nanoparticles influenced the 3D fold of the protein, resulting in at least partial unfolding. Consequently, this conformational change influenced the allergenic response, as observed by mediator release assays employing the sera of patients and immune effector cells. For an in-depth understanding of the bio-nano interactions, the properties of the particles need to be considered not only regarding the identity and morphology of the material, but also their nanotopography, given that porosity may greatly influence the structure, and hence the biological behaviour of the bound proteins. Thus, thorough structural investigations upon the formation of protein corona are important when considering immunological outcomes, as particle binding can influence the allergenic response elicited by the bound allergen.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34854455 PMCID: PMC8675021 DOI: 10.1039/d1nr05958k
Source DB: PubMed Journal: Nanoscale ISSN: 2040-3364 Impact factor: 7.790
Amount of recombinant protein and NPs used in the different experiments
| Experiment | Concentration MSNPs | Concentration NSNPs | Concentration Bet v 1 | Protein/NP ratio |
|---|---|---|---|---|
| Binding capacity | 100 μg mL−1 | 100 μg mL−1 | 10–80 μg mL−1 | 10–80% |
| CD spectroscopy | 1 mg mL−1 | 1 mg mL−1 | 100 μg mL−1 | 10% |
| Two-step ACE | 4 mg mL−1 | 8 mg mL−1 | 1 mg mL−1 | 12.5–25% |
| Limited proteolysis MS | 400 μg mL−1 | 1 mg mL−1 | 100 μg mL−1 | 10–25% |
| Bet v 1 ELISA | 400 μg mL−1 | 1 mg mL−1 | 100 μg mL−1 | 10.25% |
| huRBL | 0.0004–4000 ng mL−1 | 0.01–10 000 ng mL−1 | 0.0001–1000 ng mL−1 | 10–25% |
Physicochemical properties of used NPs including particle size, zeta potential without and with bound protein and average pore size
| Particle type | Primary size TEM [nm] | Mean size NTA [nm] | Zeta potential [mV] | Zeta potential + Bet v 1 [mV] | Mean pore size BET [nm] | Mean pore size TEM [nm] | Surface area [m2 g−1] |
|---|---|---|---|---|---|---|---|
| MSNPs | 74.9 ± 9.5 | 201 ± 12 | −12.7 ± 4.2 | −25.7 ± 2.4 | 3.9 | 4.1 ± 0.3 | 1259.8 |
| NSNPs | 133.8 ± 14.8 | 184 ± 40 | −22.1 ± 4.0 | −25.5 ± 6.3 | — | — | 24.8 |
Fig. 1Physicochemical characterisation of the two types of SiO2 nanoparticles. (a) Size determination of primary particles of mesoporous SiO2 NPs (MSNPs) by transmission electron microscopy (TEM). (b) Close view of MSNPs and pores using high-resolution TEM. (c) Size determination of primary particles of non-porous SiO2 NPs (NSNPs) by TEM. (d) Size distribution of both SiO2 NPs in solution using nanoparticle tracing analysis (NTA).
Fig. 2Binding selectivity and Bet v 1-binding capacity of NPs. (a) Schematic representation of the experimental setup. (b) SDS-PAGE of birch pollen extract (BPE) incubated with SiO2 NPs. Lane M: protein marker; lane 1: BPE bound to MSNPs; lane 2: BPE only; lane 3: BPE bound to NSNPs. (c) Immunoblot using anti-Bet v 1 monoclonal mouse antibodies for the detection of Bet v 1. Lane M: protein marker; lane 1: BPE bound to MSNPs; lane 2: BPE only; lane 3: BPE bound to NSNPs; and lane 4: recombinant Bet v 1. (d) Intensity of bands 1–5 of BPE bound to SiO2 NPs relative to the intensities of BPE only bands. (e) Binding capacity of SiO2 NPs for recombinant Bet v 1 (e.g., 10% values refer to 10 μg mL−1 protein per 100 μg mL−1 NPs).
Fig. 3Impact of SiO2 NP binding on the 3D fold of the allergen. (a) Schematic representation of the experimental setup. (b) Far UV-circular dichroism spectra of unbound Bet v 1 (Bet v 1 only in black) or bound to MSNPs (blue) and NSNPs (red) spectra were recorded in the presence of 0.5 M urea (dashed lines). (c) Two-step analytical cascade of enzymes assay of unbound Bet v 1 (lanes 5 + 6) or bound to MSNPs (lanes 1 + 2) and NSNPs (lanes 3 + 4), where all samples were analysed untreated (lanes (1, 3, and 5) and upon prior treatment with 0.5 M urea (lanes 2, 4, and 6).
Fig. 4Limited proteolysis of allergen–SiO2 NP conjugates vs. Bet v 1 only. (a) Schematic representation of the experimental setup. (b) Sequence coverage maps of the ten most intense (by relative abundance) proteolytic peptides upon 5 s partial digestion using trypsin and legumain. (c) Sequence coverage maps of the ten least intense (by relative abundance) proteolytic peptides upon 5 s partial digestion using trypsin and legumain. MSNP–allergen conjugates in red, NSNP conjugates in blue, and unbound Bet v 1 in black.
Fig. 5Accessibility of monoclonal antibody (mAb) epitopes of Bet v 1 bound to MSNPs (dark grey bars) and to NSNPs (light grey bars) in comparison to the unbound Bet v 1 control (black bars) determined by ELISA using (a) BIP 1, (b) #2, (c) #11, and (d) 5H8 anti-Bet v 1 mAbs. Values are expressed as % of mAb binding normalized to unbound Bet v 1. Values represent means of n = 3 with SD, statistical significance is indicated as ns p > 0.05, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001, ****p ≤ 0.0001.
Fig. 6Impact on allergenic response after nanoparticle binding determined by mediator release assay. (a) Schematic representation of the underlying mechanism. (b) Data represented as protein concentrations needed for the half-maximum release of β-hexosaminidase compared to release using 0.1% Triton X-100.